Abstract
The transcription factor hypoxia-inducible factor HIF1A induces cardioprotection from ischemia and reperfusion injury. Here, we investigate tissue-specific pathways that are critical for HIF1A-elicited tissue protection. Initial studies showed that mice with induced global Hif1a deletion (Hif1aloxP/loxP UbiquitinCre+) have exaggerated myocardial injury during in situ ischemia and reperfusion. Surprisingly, this phenotype was mirrored only in mice with myeloid-specific Hif1a deletion (Hif1aloxP/loxP LysM Cre+). In contrast, mice with myocardial specific (Hif1aloxP/loxP Myosin Cre+), or vascular Hif1a deletion (Hif1aloxP/loxP VEcadherin Cre+) experienced similar levels of injury as controls. Subsequent studies using adoptive transfer of Hif1a-deficient polymorphonuclear neutrophils (PMNs) prior to myocardial injury demonstrated increased reperfusion injury. On the contrary, the adoptive transfer of PMNs treated ex vivo with the hypoxia inducible factor (HIF) stabilizer dimethyloxalylglycine (DMOG) was associated with attenuated myocardial injury. Furthermore, DMOG-mediated cardioprotection was abolished in Hif1aloxP/loxP LysM Cre+ mice, but not in Hif2aloxP/loxP LysM Cre+ mice. Finally, studies of PMN-dependent HIF1A target genes implicated the neuronal guidance molecule netrin-1 in mediating the cardioprotective effects of myeloid HIF1A. Taken together, the present studies identified a functional role for myeloid-expressed HIF1A in providing cardioprotection during ischemia and reperfusion injury, which is mediated, at least in part, by the induction of the netrin-1 neuronal guidance molecule in neutrophils.
Introduction
Myocardial infarction remains one of the leading causes of death worldwide. Most commonly, it is an aftereffect of a coronary artery occlusion leading to myocardial ischemia (1). As a consequence of ischemia, myocardial tissue develops profound hypoxia (2), leading to tissue necrosis if blood flow is not restored in time. During myocardial ischemia, tissue hypoxia becomes a strong transcriptional stimulus that activates a coordinated transcriptional program that promotes increased resistance to ischemia and reperfusion injury (3, 4). A central role in the coordination of this adaptive response is mediated by the stabilization of the hypoxia-inducible transcription factor HIF1A (5).
Under normoxic conditions, HIF1A is constantly degraded through the proteasomal pathway due to hydroxylation by prolylhydroxylases (PHDs), causing subsequent binding of the von Hippel Lindau gene product, which targets HIF1A for degradation (6, 7). However, when oxygen levels drop, PHDs become inactivated and HIF1A is rapidly stabilized, translocates to the nucleus, and binds to the promoter region of hypoxia inducible factor (HIF) target genes to induce their transcription (2, 3). HIF1A is known to regulate a wide array of genes. For example, gene expression profiles in endothelial cells exposed to normoxia or hypoxia indicate that more than 600 target genes are regulated by HIF1A, including gene repression or induction (8). In cardiomyocytes, HIF1A increases the expression of glycolytic pathway enzymes, thereby enhancing their capacity to generate ATP under anaerobic conditions and promoting their ability to cope with ischemic tissue injury (9). In myeloid cells, HIF1A transcriptional activity can regulate cell functions or drive the release of cardioprotective HIF1A target genes (10–12), which can significantly influence inflammatory processes (13). For example, stabilization of HIF1A in hypoxia increases the life span of usually short-lived polymorphonuclear neutrophils (PMN) (14). Furthermore, stabilization of HIF1A increases the motility of myeloid cells toward a chemotactic gradient, bringing them to the site of injury (15, 16).
Based on studies implicating HIF1A stabilization in tissue adaptation and protection during hypoxia or inflammation (3, 17, 18), research efforts were initiated to use this pathway as a therapeutic target. Several pharmaceutical companies have been successful in finding small molecule inhibitors for PHDs that can be used as HIF activators. In fact, several recent phase-3 clinical trials successfully tested the PHD inhibitors roxadustat or vadadustat for the treatment of renal anemia (19–22). Furthermore, experimental studies provide evidence that PHD inhibitors induce cardioprotection from ischemia and reperfusion injury (5, 23). Together, these studies highlight that the HIF1A pathway could be utilized as a therapeutic target for myocardial ischemia and reperfusion injury.
Cardioprotection by HIF1A is supported by several previous studies (24–26). However, the cellular source of HIF-mediated cardioprotection remains unknown. HIF1A is ubiquitously expressed, including cells involved in myocardial ischemia and reperfusion injury, such as cardiomyocytes, vascular endothelial cells, and myeloid cells (23, 27). To uncover the individual contributions of different cellular compartments during HIF1A-dependent cardioprotection, we used transgenic mice with a Hif1a gene flanked by a LoxP site. When breeding these mice with tissue-specific expression of Cre recombinase, we stepwise deleted Hif1a from different cellular compartments. Surprisingly, we found that the predominant source of HIF1A-mediated cardioprotection involves myeloid cells and uncovered a novel contribution of PMN.
Materials and methods
Mice
All animal procedures were performed in an accredited facility of the American Association for Laboratory Animal Care and approved by the University of Colorado Denver and the Institutional Animal Care and Use Committee of the University of Texas Health Science Center at Houston (UTHealth). For all studies, we used mice with an age of 8–16 weeks. C57BL/6J mice were purchased from The Jackson Laboratory (Bar Harbor, ME, United States). Hif1aloxP/loxP (B6.129-Hif1aTM3Rsjo/J) (28), Hif2aloxP/loxP (Epas1tm1Mcs/J) (23), Ntn1loxP/loxP (B6.129(SJL)-Ntn1tm1.1Tek/J) (12). These animals were crossed with the following mouse lines, that express Cre-recombinase under the control of a tissue-specific promoter: tamoxifen-inducible Ubiquitin Cre+ (B6.Cg-Ndor1Tg (UBC-cre/ERT2) 1Ejb/J) (29), LysM Cre+ (B6.129P2-Lyz2TM 1 (cre)Ifo/J) (30), VE-cadherin-Cre+ (B6.Cg-Tg(Cdh5-cre)7Mlia/J) (31, 32), and tamoxifen inducible Myosin-Cre+ (B6.FVB(129)-A1cfTg). For studies using Myosin-Cre+ or Ubiquitin Cre+ mice, mice received tamoxifen dissolved in peanut oil for 5 days (1 mg/day i.p.), followed by a resting period of 7 days prior to experimentation. Mice were genotyped by GeneTyper (New York, NY, United States) or in house according to the recommended protocol.
Human neutrophil isolation and cell culture
From healthy subjects, human blood was collected in tubes containing anticoagulant citrate (S-monovette #04.1902, Sarstedt, Nümbrecht, Germany). Neutrophils were isolated using a Percoll-based protocol. Briefly, whole blood was applied to the discontinuous Percoll gradient containing equal vols of 63 and 72% Percoll solution and centrifuged at 400 (× g) for 30 min without brake. A mixture of neutrophils and red blood cells was collected at the Percoll gradient interface, in which the latter were subsequently removed by isotonic lysis (NH4Cl solution). Neutrophils were then pelleted and washed with HBSS(-). Neutrophil purity/viability was assessed by loading a small aliquot into a particle count and size analyzer (Coulter, Backman Coulter) following the manufacturer’s instructions. In total, 1–2 × 106 PMN per ml of blood were typically isolated with >95% purity and viability. After isolation, neutrophils were rested 30 min before experiments. Cells were cultured 2.5 × 106 cells/ml in RPMI 1640 with 10% FCS at 37°C in 21% O2 (0 h timepoint) or 2% O2 (hypoxia timepoints).
Murine model for myocardial ischemia
A detailed procedure of in situ myocardial ischemia and reperfusion injury has previously been described (23, 33–35). In summary, we exposed mice to 60 min of myocardial ischemia followed by 2 h of reperfusion, followed by an analysis of the size of the infarct and a measurement of cardiac troponin I (cTnI) in serum. Dimethyloxalylglycine (DMOG) was administered to mice 4 h before ischemia started (1 mg/mouse, dissolved in normal saline, intraperitoneal). Successful occlusion of LCA occlusion was confirmed by a color change in LCA-supplied cardiac tissue. After 60 min of ischemia, the weights were removed to allow reperfusion of the tissue. During ischemia, we administered normal saline at a constant rate of 0.1 ml/h. At the beginning of reperfusion, we increased the infusion rate to 0.6 mL/h.
Infarct staining
The detailed procedure to measure the percentage of infarcted area relative to the area undergoing ischemia (area at risk) using a counterstain technique was previously described (23, 33). At the end of the experiment, the circulation was flushed with 5 ml of normal saline and LCA was permanently occluded. After injection of Evan’s blue dye (600 μl, 1%), the heart was excised by the heart basis and kept at −20°C for 15 min. The hearts were then cut and incubated with 1% triphenyltetrazolium chloride (TTC) for 10 min at 37°C before fixation in 4% neutral buffer formalin. To prevent bleaching of the dye, photographs of the heart slices were taken the day after the experiments. For this, tissue slices were placed between glass slides and pictures were taken using a Nikon D5300 camera at 32× magnification. The AAR and infarct size were measured by ImageJ software (National Institutes of Health, United States; Version 1.51k). If an air bubble was accidentally injected into the cardiac circulation during Evan’s blue injection, resulting in incomplete delimitation of AAR, the sample was excluded.
Cardiac troponin I enzyme-linked immunosorbent assay
As an additional line of evidence for myocardial injury, cTnI was measured by enzyme-linked immunosorbent assay (ELISA), as described (36) using the cTnI ELISA Kit (Life Diagnostic, #CTNI-1-HS).
Neutrophil depletion and adoptive transfer
Untouched PMNs were isolated from bone marrow in donor mice of the indicated genotype (aged 6–8 weeks) using the EasySep mouse neutrophil enrichment kit (Stemcell Technologies Inc.). In a subset of the experiment PMN from C57/J animals, 1 mM DMOG (Sigma-Aldrich, #D3695) or vehicle solution was incubated for 60 min. Then 1 × 106 cells were injected into neutrophil-depleted mice through an arterial catheter over a 10-min period 60 min prior to myocardial ischemia. The detailed procedure for neutrophil depletion in vivo was previously described (37) using Ly6G-specific mAb 1A8 antibody (BioXCell).
Immunoblotting experiments
To study the expression of Netrin-1, immunoblotting methods were conducted. At the end of each timepoint, neutrophils in the medium were collected and centrifuged at 500 (× g) for 5 min to collect cells. Cells were immediately lysed in IP lysis buffer (Pierce #87788, ThermoFisher) on ice for 30 min and then centrifuged at 12,000 (× g) for 10 min. The protein concentration of the lysates was measured by the BCA Assay (#23225, ThermoFisher) then incubated in Laemmli sample buffer containing 2-mercaptoethanol at 95°C for 5 min. Lysate proteins (40 μg) were separated on 7.5% SDS polyacrylamide gels by SDS-PAGE and then transferred to PVDF membranes using a Bio-Rad Mini Trans-Blot cell. Netrin-1 (LSBio, LS-C743016) and β-actin (Santa Cruz, sc-130656), used as loading control, were detected using specific primary antibodies. The membranes were subsequently incubated with a secondary antibody coupled to HRP conjugate (Invitrogen #65-6120). The membranes were incubated with ECL reagents (Clarity Max, Bio-Rad, and Immunocruz, Santa Cruz, respectively) and the chemiluminescent signal detected by the Fusion Imaging System (Vilber Lourmat). Protein expression was quantified by densitometry using ImageJ (National Institutes of Health, United States; Version 1.51k) and normalized to the expression of β-actin.
Statistical analysis
The N numbers were predetermined by power analysis to detect a mean difference of 20% with 8% standard deviation (SD). Outliers were detected by the Grubb test and removed from the data. All data approximately followed the normal distribution and were plotted as mean ± SD. The experimental data were analyzed by the unpaired two-sided student t-test or ANOVA with Tukey test for multiple comparison. A p-value less than 0.05 was considered statistically significant. Statistical analyzes were performed using Prism (version 9.1.2, GraphPad Software Inc.).
Results
Global-induced deletion of Hif1A is associated with increased myocardial ischemia and reperfusion injury
Previous studies have implicated HIF1A in cardioprotection from ischemia and reperfusion injury (5, 23, 38). For example, mice with Hif1a heterozygote deletion are not protected by ischemic preconditioning (39). Similarly, pharmacologic stabilizers of HIF, such as DMOG, provide robust cardioprotection during ischemia and reperfusion (5). However, the fact that mice with Hif1a homozygous deletion die during embryogenesis (40) has made it difficult to provide direct genetic evidence for Hif1a during cardioprotection. Thus, we generated mice with induced global deletion of Hif1a after tamoxifen treatment by crossing Hif1aloxP/loxP mice with Ubiquitin Cre+ mice to generate Hif1aloxP/loxP Ubiquitin Cre+ mice (41). To achieve global-induced Hif1a deletion, mice were treated daily with tamoxifen for 5 days (1 mg i.p./day) and recovered for 7 days before myocardial ischemia and reperfusion injury, using a previously described in situ model (Figure 1A) (34). Western blot analysis for Hif1a showed the expression of the Hif1a protein in response to Hif1a stabilizer treatment (DMOG, 1 mg i.p.) in Ubiquitin Cre+ mice. On the contrary, the Hif1a protein did not accumulate in cardiac tissue in Hif1aloxP/loxP Ubiquitin Cre+ mice after DMOG treatment (Figure 1B), suggesting a successful deletion of Hif1a in these animals.
FIGURE 1
To assess the functional consequences of global-induced deletion of Hif1a in myocardial ischemia and reperfusion injury, we exposed Hif1aloxP/loxP Ubiquitin Cre+ mice to in situ myocardial ischemia and reperfusion after treatment and recovery with tamoxifen (Figure 1A) and evaluated myocardial injury by infarct sizes and serum troponin levels. These studies demonstrated significantly larger myocardial infarct sizes after 60 min of ischemia and 2 h of reperfusion in Hif1aloxP/loxP Ubiquitin-Cre+ mice compared to littermate control Ubiquitin Cre+ mice after tamoxifen treatment (Figures 1C,D). Similarly, Hif1aloxP/loxP Ubiquitin Cre+ mice experienced significantly elevated of the cardiac injury marker troponin I (Figure 1E). Together, these studies demonstrate that Hif1a induced deletion is associated with dramatic increases in myocardial injury after ischemia and reperfusion, and confirm previous studies implicating HIF1A in cardioprotection (5, 38).
Tissue-specific Hif1a deletion reveals a selective role for myeloid-derived Hif1A in mediating cardioprotection during ischemia and reperfusion
Based on the above studies showing that global-induced deletion of Hif1A has deleterious effects during in situ myocardial ischemia and reperfusion injury, we next pursued studies to identify tissue-specific contributions of Hif1a in cardioprotection. To do this, we generated mice with Hif1a deletion in different tissue compartments, including cardiomyocytes (Hif1aloxP/loxP Myosin Cre+ mice) (23), vascular endothelial cells (Hif1aloxP/loxP VEcadherin Cre+ mice) (27) or myeloid cells (Hif1aloxP/loxP LysM Cre+ mice) (42). We subjected these mouse lines with Cre+ control mice of the same sex, weight, and age to 60 min of myocardial ischemia and 120 min of reperfusion and measured myocardial injury by assessing the size area of the infarct and serum troponin levels, as previously (12, 23, 35, 43). Consistent with previous studies (23), we found that Hif1aloxP/loxP Myosin Cre+ mice had similar infarct sizes and troponin I levels compared to Myosin Cre+ controls (Figures 2A–C). Similarly, deletion of Hif1a in vascular endothelia (Hif1aloxP/loxP VEcadherin Cre+ mice) did not alter the susceptibility to myocardial injury (Figures 2D–F). Surprisingly, we found the predominant phenotype in mice with Hif1a deletion in the myeloid compartment. Indeed, Hif1aloxP/loxP LysM Cre+ mice had dramatic increases in myocardial infarct sizes, and increased troponin I leakage into the plasma, as compared to LysM Cre+ control animals (Figures 2G–I). Together, these studies provide novel evidence that mice with myeloid-specific Hif1a deletion experience increased susceptibility to myocardial ischemia and reperfusion injury, essentially resembling the findings in mice with induced global deletion of Hif1A (Figures 1C–E).
FIGURE 2
Transfer of Hif1a-deficient polymorphonuclear neutrophils is associated with more severe myocardial ischemia and reperfusion injury
The above studies indicate myeloid-dependent HIF1A in cardio-protection from ischemia and reperfusion injury. As next step, we pursued studies to further characterize specific cellular populations that are critical in this response. Due to the fact that PMNs are the predominant bone marrow-derived inflammatory cells in the post-ischemic myocardium (36), we next performed studies to address PMN-dependent HIF1A. For this purpose, we performed an adoptive transfer as described previously (43). In short, C57BL6J animals received 250 μg of 1A8 Ly6G-antibody 24 h prior to experimentation to deplete PMNs. On the day of the experiment, we isolated a pure population of mature PMNs from Hif1aloxP/loxP LysM Cre+ or matched wild-type control mice and infused via an intravascular catheter into PMN-depleted animals followed by 60 min of myocardial ischemia followed by 2 h of reperfusion (Figure 3A). In line with a functional role of HIF1A expressed in PMNs, we found that reconstitution with Hif1a-deficient PMNs was associated with dramatically increased infarcts sizes, when compared to mice reconstituted with control PMNs (Figures 3B,C), resembling myocardial injury phenotypes in Hif1aloxP/loxP LysM Cre+ mice. Together, these results indicate that PMN-dependent Hif1a deficiency is associated with elevated myocardial ischemia and reperfusion injury and implicates PMN-dependent HIF1A in cardioprotection.
FIGURE 3
Pharmacologic stabilization of hypoxia inducible factor in isolated polymorphonuclear neutrophils prior to myocardial injury confers cardioprotection
Based on the above studies showing that reconstitution with Hif1A-deficient PMNs prior to myocardial injury is associated with more severe myocardial infarction after ischemia and reperfusion, we next pursued opposite studies using PMNs treated ex vivo with a pharmacologic HIF activator. For this purpose, we used the HIF stabilizer DMOG. Previous studies from our laboratory had shown that systemic treatment with DMOG provides cardioprotection via stabilization of HIF1A (5, 23, 38). Similar to the experimental approach above, we first pursued PMN depletion prior to the experimentation by injecting mice with 250 μg of 1A8 Ly6G-antibody 24 h prior to myocardial ischemia and reperfusion. We isolated PMNs from C57BL6J mice and subsequently exposed PMNs for 60 min to vehicle or 1 mM DMOG (44). After the incubation period, we performed an adoptive transfer into PMN-depleted mice followed by 60 min of in situ ischemia and 120 min of reperfusion (Figure 4A). Mice that had received PMNs pre-treated with DMOG had significantly attenuated myocardial injury as compared to vehicle controls (Figures 4B,C). Taken together, these studies highlight that adoptive transfer of ex vivo DMOG treated PMNs before myocardial ischemia and reperfusion is associated with attenuated reperfusion injury and suggests a functional role of PMN-dependent HIF in cardioprotection.
FIGURE 4
Selective role of myeloid HIF1A deficiency in mediating the cardioprotective effects of prolylhydroxylase-inhibitor treatment dimethyloxalylglycine
Previous studies have implicated both isoforms of HIFA (HIF1A or HIF2A) in cardio-protection from ischemia and reperfusion injury, including protective effects mediated by treatment with HIF stabilizers such as DMOG (5, 23, 35). To gain insight into the relative contributions of myeloid-expressed Hif1a or Hif2a in mediating DMOG elicited cardioprotection, we compared Hif1aloxP/loxP LysM Cre+ or Hif2aloxP/loxP LysM Cre+ on their capacity for infarct size reduction provided by pre-treatment with DMOG. In these studies, Hif1aloxP/loxP LysM Cre+, or Hif2aloxP/loxP LysM Cre+ were pre-treated with 1 mg DMOG i.p. or vehicle control 4 h before myocardial ischemia. Subsequently, animals were exposed to 60 min of myocardial ischemia and 120 min of reperfusion. In line with a functional role of myeloid-expressed Hif1a in mediating DMOG-protection we found that Hif2aloxP/loxP LysM Cre+ mice are responsive to DMOG pre-treatment with reduced ischemia and reperfusion injury compared to vehicle, as demonstrated in myocardial infarct sizes and troponin I-leakage (Figures 5A–C). In contrast, we found that Hif1aloxP/loxP LysM Cre+ failed to respond to pre-treatment with DMOG. Myocardial infarct size of Hif1aloxP/loxP LysM Cre+ pre-treated with DMOG were similar to that of Hif1aloxP/loxP LysM Cre+ pretreated with vehicle control (Figures 5D–F). Taken together, these results indicate that myeloid HIF1A as opposed to myeloid HIF2A is required for the cardio-protection provided by PHD inhibitors. In conjunction with our studies showing attenuated infarct sizes after ex vivo treatment with HIF stabilizer, these findings provide additional data implicating PMN-dependent HIF1A in cardio-protection from ischemia and reperfusion injury.
FIGURE 5
Identification of neuronal guidance molecule netrin-1 as polymorphonuclear neutrophil-dependent Hif1A target critical for hypoxia inducible factor-dependent cardioprotection
Based on the above studies demonstrating functional roles of neutrophil-dependent HIF1A in cardioprotection from ischemia and reperfusion, we subsequently pursued studies to identify a transcriptional target in PMNs that would account for these observations. Recent studies from our laboratory had shown that PMN-derived netrin-1 functions to attenuate in situ myocardial ischemia and reperfusion injury. Netrin-1 was originally described as a neuronal guidance molecule important in brain development (45). However, more recent studies implicate netrin in orchestrating inflammatory events, including myocardial inflammation (46). Moreover, other studies had implicated HIF1A in the transcriptional regulation of netrin-1 during hypoxia, and identified netrin-1 as a classic HIF-target gene (42, 47). To examine a functional role of hypoxia-signaling in inducing PMN-dependent netrin-1, we first examined expression of netrin-1 during condition of ambient hypoxia. For this purpose, we freshly isolated human PMNs from peripheral blood and submitted the cells to 0, 2, and 4 h of ambient hypoxia (2% oxygen) and probed the cell lysates for netrin-1 expression by Western blot. Consistent with previous studies showing induction of netrin-1 expression during hypoxia (47), we found a very robust induction of PMN-dependent netrin-1 during ambient hypoxia (Figures 6A,B). Recent studies from our laboratory demonstrated the mice with deletion of myeloid-expressed netrin-1 (Ntn1loxP/loxP LysM Cre+ mice) experience increased myocardial infarct sizes and show that elevated levels of netrin-1 during myocardial infarction predominantly stems from PMNs (12). To further establish a link between the HIF-pathway and myeloid-dependent netrin-1 during cardioprotection, we next pursued studies with the pharmacologic HIF stabilizer DMOG. Here, we hypothesized that if myeloid-dependent HIF functions through induction of netrin-1 to provide cardioprotection, the cardioprotective effects of DMOG would be abolished in Ntn1loxP/loxP LysM Cre+ mice. To address this hypothesis, we treated Ntn1loxP/loxP LysM Cre+ mice with DMOG (1 mg i.p. 4 h prior to myocardial ischemia) or vehicle control, a treatment protocol that we had previously shown to be effective in reducing myocardial infarct sizes (5, 23). Consistent with a functional role of PMN-dependent netrin-1 in mediating DMOG-dependent cardioprotection, we found that the previously shown reduction of myocardial infarct sizes associated with DMOG treatment (Figures 5A–C) (5, 23) were completely abolished in Ntn1loxP/loxP LysM Cre+ mice (Figures 6C–E). Together with recent studies from our laboratory showing that Ntn1loxP/loxP LysM Cre+ mice experience increased infarct sizes (12), these findings implicate HIF-dependent induction of netrin-1 in the cardioprotection provided by myeloid-expressed HIF1A during ischemia and reperfusion injury of the heart.
FIGURE 6
Discussion
Hypoxia-inducible factors such as HIF1A have been implicated in tissue adaption during limited oxygen availability, inflammation, or ischemia and reperfusion injury (48). While previous studies have directly implicated HIF1a in limiting myocardial infarct sizes during ischemia and reperfusion injury (5, 38, 39, 49, 50), the relative contributions of HIF1A expressed in different cell types in the heart remain elusive. To investigate tissue-specific functions of HIF1A in cardioprotection from in situ ischemia and reperfusion injury, we took a stepwise approach. In initial studies, we used a genetic approach, where Hif1A deletion was induced in the adult mouse, thereby circumventing embryonic lethality of homozygote Hif1a deletion (40). These studies revealed dramatic increase of myocardial infarct sizes in mice with induced global Hif1A deletion (Hif1aloxP/loxP UbiquitinCre+ mice) as compared to Cre+ controls. As second step, we pursued studies of myocardial ischemia and reperfusion injury in mice with genetic deletion of Hif1a in different tissue compartments, including cardiomyocytes (Hif1aloxP/loxP Myosin Cre+ mice), vascular endothelial cells (Hif1aloxP/loxP VEcadherin Cre+ mice) or in myeloid inflammatory cells (Hif1aloxP/loxP LysM Cre+ mice). To our surprise, only mice with deletion of Hif1a in myeloid inflammatory cells resembled the previous findings we had established in mice with induced global deletion of Hif1A, thereby indirectly implicating myeloid-dependent Hif1a in cardio-protection from ischemia and reperfusion. Due to the critical functions and high presence of PMNs during myocardial reperfusion injury (51), we studied mice with reconstitution of wild-type or Hif1a-deficient neutrophils following antibody-mediate PMN depletion (52). While mice with Hif1a-deficient PMNs experience increased myocardial injury, mice with reconstitution of wild-type PMN that received ex vivo treatment with HIF stabilizer DMOG were protected. Finally, studies that focused on transcriptional targets of HIF1A in neutrophils implicated PMN-dependent netrin-1 in mediating HIF1A elicited cardioprotection. Together, these studies highlight a functional role of myeloid-dependent HIF1A in attenuating myocardial ischemia and reperfusion, and its transcriptional target netrin-1. Based on these studies, using HIF stabilizers or treatment with recombinant netrin-1 may represent novel approaches to treat or prevent myocardial injury during myocardial ischemia and reperfusion.
Netrin-1 improves the signaling events of the adenosine receptor Adora2b (53), which elicits strong anti-inflammatory effects, as previous studies have shown (47). In recent studies, netrin-1 was shown to require a functional Adora2b receptor on the surface of neutrophils to induce cardio protective effects (12). Likewise, Adora2b was previously identified as the target for hypoxia signaling through HIF1A. Studies of murine models of myocardial infarction and reperfusion injuries demonstrate the strong cardiovascular protection of Adora2b. A specific agonist for Adora2b significantly reduced the size of infarct after myocardial ischemia (5). Studies using the HIF activator DMOG as a treatment approach for experimental myocardial ischemia showed that cardioprotection was eliminated in mice lacking Adora2b (5). This directly links the signaling of HIF1A and ADORA2B during cardioprotection.
Adora2b reduces the size of the infarct due to its strong inhibition of the inflammatory response. This has been demonstrated in studies in which Adora2b deficiency in mice increased the expression of pro-inflammatory and cardiotoxic cytokine tumor necrosis factor alpha (TNF-α) (36). Netrin-1 has similar anti-inflammatory effects in hypoxic inflammation that require the presence of ADORA2B (47) – and both Netrin-1 and ADORA2B are HIF1a-target genes. This suggests that, in response to myocardial infarction and reperfusion, activation of HIF1A coordinates cardioprotective effects by activating the expressions of Netrin-1 and ADORA2B, which both reduce post-ischemic myocardial inflammation.
While the current studies directly implicate HIF1A in attenuating myocardial ischemia and reperfusion injury, other studies have also implicated HIF2A in cardioprotection. HIF2A is an isoform of HIF1A and several studies have identified either complementary or opposing functions to HIF1A (35, 54–57). As such, it is not surprising that previous studies have also identified a functional role of Hif2A in attenuating myocardial infarct sizes during ischemia and reperfusion injury (23). In contrast to the current studies that implicated myeloid-dependent Hif1A in cardioprotection, those studies demonstrated a functional role of HIF2A expressed in cardiac myocytes. In fact, Hif2aloxP/loxP Myosin Cre+ mice exhibited larger infarct sizes during in situ myocardial ischemia and reperfusion injury (23). Subsequent studies on myocyte-dependent HIF2A target genes implicate the epidermal growth factor amphiregulin (AREG) in mediating HIF2A dependent cardioprotection (23). Additional studies in myocardial biopsies of patients with ongoing ischemia revealed elevated levels of AREG (23), of the amphiregulin receptor ERBB1 (35). Mice with global deletion of Areg (Areg–/– mice), or with deletion of the ErbB1 receptor expressed on cardiac myocytes (ErbB1loxP/loxP Myosin Cre+) experienced increased susceptibility to myocardial ischemia and reperfusion injury. Together, those studies implicate myocyte-dependent HIF2A in coordinating the induction and signaling events of AREG through the ERBB1 receptor in cardioprotection (23, 35). Together with the current studies, those findings accentuate a cardioprotective role of HIF, by attenuating myocardial ischemic injury through myocyte-dependent HIF2A and myocardial reperfusion injury through myeloid-dependent HIF1A.
While the current studies concentrate on myocardial ischemia and reperfusion injury, previous studies had also implicated HIF in promoting ischemic preconditioning of the heart. Ischemic preconditioning involves short episode of ischemia that confers protection to a subsequent myocardial infarction (58). Several previous studies have shown functional roles of HIF1A in mediating the tissue-protective effects of ischemic preconditioning, including studies to address tissue-specific functions of HIF1A. Initial studies demonstrated that mice with partial deletion of Hif1a (Hif1a± mice) experienced a complete loss of cardioprotection from ischemic preconditioning (26). Similarly, mice with siRNA in vivo silencing of Hif1a demonstrated a lack of cardio-protection by ischemic preconditioning, while pre-treatment with the HIF stabilizer DMOG preconditioned the myocardium (5). Subsequent studies to address tissue-specific functions of HIF1A in ischemic preconditioning implicated HIF1A activity in vascular endothelia (50). Other studies found that deletion of Hif1a in cardiomyocytes (Hif1aloxP/loxP Myosin Cre+) also abolishes the cardio-protective effects of ischemic preconditioning (23). In contrast, mice with cardiomyocyte-specific deletion of Hif2a (Hif2aloxP/loxP Myosin Cre+) were protected by ischemic preconditioning (23). Interestingly, more recent studies also implicate HIF1A in mediating the cardioprotective effects of remote ischemic preconditioning, where repeated episodes of remote ischemia to a limb can produce protection from myocardial or acute kidney injury (59). These studies indicate that during remote ischemic preconditioning, HIF1A is stabilized, and transcriptionally induces the HIF target gene L-10 with subsequent IL-10 signaling as a mechanism of cardioprotection (49). Taken together, these studies provide evidence from multiple studies that HIF1A – as opposed to HIF2A – mediates the cardioprotective effects of direct or remote ischemic preconditioning (17, 60).
The current studies implicate the HIF1A target netrin-1 in PMNs as critical target for mediating the cardioprotective effects of myeloid HIF1A. Netrin-1 is a neuronal guidance molecule that was initially described as a diffusible axon outgrowth promoting factor in nematodes (61). However, it became apparent that netrin-1 is much more ubiquitously expressed (62). In addition to its function as neuronal guidance molecule during brain development (45), it became apparent that netrin-1 can also function to modulate inflammatory endpoints or ischemia and reperfusion injury (63, 64). For example, netrin-1 released from the vagal nerve has been shown to attenuate excessive inflammation and promote the resolution of injury (64). Several previous studies have linked netrin-1 signaling in cardioprotection from ischemia and reperfusion injury, for example via interaction of netrin-1 with the classic netrin-1 receptor deleted in colorectal cancer DCC expressed on endothelial cells (65, 66). Consistent with current findings, a recent study indicates that PMN-dependent netrin-1 can function to provide cardioprotection during in situ ischemia and reperfusion injury by enhancing extracellular adenosine signaling events through the Adora2b adenosine receptor (12, 53, 63, 67, 68). Although extracellular adenosine signaling was initially described to induce a transient slowing of heart rate (69), many subsequent studies have sown functional roles for extracellular adenosine signaling in attenuating myocardial ischemia and reperfusion injury, including studies directly implicating myeloid Adora2b signaling (7, 36, 43) (Figure 7). Taken together, these studies provide additional support for the concept that myeloid HIF1A provides cardioprotection through transcriptional induction of its target gene netrin-1, leading to attenuated myocardial ischemia and reperfusion injury.
FIGURE 7
The current findings have important translational implications. For example, it is possible that patients experiencing myocardial ischemia and reperfusion injury could be treated with recombinant netrin-1 to activate the HIF1A-netrin-1 pathway for cardioprotection. Several other studies have shown that recombinant netrin-1 treatment can function to dampen myocardial injury (12) or other states of inflammatory disease (67). However, an alternative treatment approach would include the use of pharmacological HIF stabilizers. Over the past decade, several pharmaceutical companies have developed pharmacologic HIF activators (17, 18, 70–72). These pharmacological HIF activators function by inhibiting prolylhydroxylases and thus prevent the degradation of HIF1A via the proteasomal pathway (3). Pharmacological HIF activators, such as roxadustat or vadadustat, have been successfully tested for the treatment of renal anemia and phase 3 clinical trials and are available as oral medications (19–22). These orally available HIF activators could be used in patients experiencing myocardial ischemia and reperfusion injury. Furthermore, it is possible that these medications could be given to patients at high risk of experiencing myocardial injury, such as patients undergoing cardiac surgery. Treatment with an oral HIF activator would likely cause stabilization of HIF, including neutrophils, and thus dampen myocardial ischemia and reperfusion injury (73). This highlights that HIF1A coordinates the transcriptional response in response to myocardial ischemia.
Statements
Data availability statement
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.
Ethics statement
This animal study was reviewed and approved by the University of Colorado Denver and the Institutional Animal Care and Use Committee of the University of Texas Health Science Center at Houston.
Author contributions
KH-S, JL, and WR performed the experiments. XY and YW helped with data analysis. MK designed the study, performed the experiments and data analysis, and wrote the manuscript. HE designed the study and wrote the manuscript. All authors contributed to the article and approved the submitted version.
Funding
This study was supported by Deutsche Forschungsgemeinschaft (DFG; KO 3884/5-1) to MK and National Institute of Health Grants R01HL154720, R01DK122796, R01DK109574, and R01HL133900 and the Department of Defense Grant W81XWH2110032 to HE. Natural Science Foundation of Hunan Province Grant 2018JJ3736, Hunan Youth Talents Program 2021RC3034, and 2022 International Anesthesia Research Society Mentored Research Award to WR.
Acknowledgments
All schematics were generated using BioRender.com.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1.
HeuschG.Myocardial ischaemia-reperfusion injury and cardioprotection in perspective.Nat Rev Cardiol. (2020) 17:773–89. 10.1038/s41569-020-0403-y
2.
EltzschigHKCarmelietP.Hypoxia and inflammation.N Engl J Med. (2011) 364:656–65. 10.1056/NEJMra0910283
3.
EltzschigHKBrattonDLColganSP.Targeting hypoxia signalling for the treatment of ischaemic and inflammatory diseases.Nat Rev Drug Discov. (2014) 13:852–69. 10.1038/nrd4422
4.
SitkovskyMLukashevD.Regulation of immune cells by local-tissue oxygen tension: HIF1 alpha and adenosine receptors.Nat Rev Immunol. (2005) 5:712–21. 10.1038/nri1685
5.
EckleTKohlerDLehmannREl KasmiKCEltzschigHK.Hypoxia-inducible factor-1 is central to cardioprotection: a new paradigm for ischemic preconditioning.Circulation. (2008) 118:166–75. 10.1161/CIRCULATIONAHA.107.758516
6.
KoeppenMEckleTEltzschigHK.The hypoxia-inflammation link and potential drug targets.Curr Opin Anaesthesiol. (2011) 24:363–9. 10.1097/ACO.0b013e32834873fd
7.
KoeppenMEckleTEltzschigHK.Interplay of hypoxia and ADORA2B adenosine receptors in tissue protection.Adv Pharmacol. (2011) 61:145–86. 10.1016/B978-0-12-385526-8.00006-0
8.
ManaloDJRowanALavoieTNatarajanLKellyBDYeSQet alTranscriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1.Blood. (2005) 105:659–69. 10.1182/blood-2004-07-2958
9.
BonneySKominskyDBrodskyKEltzschigHWalkerLEckleT.Cardiac per2 functions as novel link between fatty acid metabolism and myocardial inflammation during ischemia and reperfusion injury of the heart.PLoS One. (2013) 8:e71493. 10.1371/journal.pone.0071493
10.
ShepardsonKMJhingranACaffreyAObarJJSurattBTBerwinBLet alMyeloid derived hypoxia inducible factor 1-alpha is required for protection against pulmonary Aspergillus fumigatus infection.PLoS Pathog. (2014) 10:16. 10.1371/journal.ppat.1004378
11.
AlexanderLECAkong-MooreKFeldsteinSJohanssonPNguyenAMcEachernEKet alMyeloid cell HIF-1 alpha regulates asthma airway resistance and eosinophil function.J Mol Med. (2013) 91:637–44. 10.1007/s00109-012-0986-9
12.
LiJConradCMillsTWBergNKKimBRuanWet alPMN-derived netrin-1 attenuates cardiac ischemia-reperfusion injury via myeloid ADORADORA2B signaling.J Exp Med. (2021) 218:e20210008. 10.1084/jem.20210008
13.
LinNSimonMC.Hypoxia-inducible factors: key regulators of myeloid cells during inflammation.J Clin Invest. (2016) 126:3661–71. 10.1172/JCI84426
14.
WalmsleySRPrintCFarahiNPeyssonnauxCJohnsonRSCramerTet alHypoxia-induced neutrophil survival is mediated by HIF-1alpha-dependent NF-kappaB activity.J Exp Med. (2005) 201:105–15. 10.1084/jem.20040624
15.
CramerTYamanishiYClausenBEForsterIPawlinskiRMackmanNet alHIF-1alpha is essential for myeloid cell-mediated inflammation.Cell. (2003) 112:645–57. 10.1016/S0092-8674(03)00154-5
16.
TaylorCTColganSP.Regulation of immunity and inflammation by hypoxia in immunological niches.Nat Rev Immunol. (2017) 17:774–85. 10.1038/nri.2017.103
17.
YuanXLeeJWBowserJLNeudeckerVSridharSEltzschigHK.Targeting hypoxia signaling for perioperative organ injury.Anesth Analg. (2017) 126:308–21.
18.
BowserJLLeeJWYuanXEltzschigHK.The hypoxia-adenosine link during inflammation.J Appl Physiol. (2017) 123:1303–20. 10.1152/japplphysiol.00101.2017
19.
ChenNHaoCPengXLinHYinAHaoLet alRoxadustat for anemia in patients with kidney disease not receiving dialysis.N Engl J Med. (2019) 381:1001–10. 10.1056/NEJMoa1813599
20.
ChenNHaoCLiuBCLinHWangCXingCet alRoxadustat treatment for anemia in patients undergoing long-term dialysis.N Engl J Med. (2019) 381:1011–22. 10.1056/NEJMoa1901713
21.
EckardtKUAgarwalRAswadAAwadABlockGABacciMRet alSafety and efficacy of vadadustat for anemia in patients undergoing dialysis.N Engl J Med. (2021) 384:1601–12. 10.1056/NEJMoa2025956
22.
ChertowGMPergolaPEFaragYMKAgarwalRArnoldSBakoGet alVadadustat in patients with anemia and non-dialysis-dependent CKD.N Engl J Med. (2021) 384:1589–600. 10.1056/NEJMoa2035938
23.
KoeppenMLeeJWSeoSWBrodskyKSKrethSYangIVet alHypoxia-inducible factor 2-alpha-dependent induction of amphiregulin dampens myocardial ischemia-reperfusion injury.Nat Commun. (2018) 9:816. 10.1038/s41467-018-03105-2
24.
EltzschigHKBonneySKEckleT.Attenuating myocardial ischemia by targeting ADORA2B adenosine receptors.Trends Mol Med. (2013) 19:345–54. 10.1016/j.molmed.2013.02.005
25.
AdluriRSThirunavukkarasuMDunnaNRZhanLOriowoBTakedaKet alDisruption of hypoxia-inducible transcription factor-prolyl hydroxylase domain-1 (PHD-1-/-) attenuates ex vivo myocardial ischemia/reperfusion injury through hypoxia-inducible factor-1alpha transcription factor and its target genes in mice.Antioxid Redox Signal. (2011) 15:1789–97. 10.1089/ars.2010.3769
26.
CaiZZhongHBosch-MarceMFox-TalbotKWangLWeiCet alComplete loss of ischaemic preconditioning-induced cardioprotection in mice with partialdeficiency of HIF-1{alpha}.Cardiovasc Res. (2007) 77:463–70. 10.1093/cvr/cvm035
27.
EckleTBrodskyKBonneyMPackardTHanJBorchersCHet alHIF1A reduces acute lung injury by optimizing carbohydrate metabolism in the alveolar epithelium.PLoS Biol. (2013) 11:e1001665. 10.1371/journal.pbio.1001665
28.
RyanHEPoloniMMcNultyWElsonDGassmannMArbeitJMet alHypoxia-inducible factor-1alpha is a positive factor in solid tumor growth.Cancer Res. (2000) 60:4010–5.
29.
RuzankinaYPinzon-GuzmanCAsareAOngTPontanoLCotsarelisGet alDeletion of the developmentally essential gene ATR in adult mice leads to age-related phenotypes and stem cell loss.Cell Stem Cell. (2007) 1:113–26. 10.1016/j.stem.2007.03.002
30.
ClausenBEBurkhardtCReithWRenkawitzRForsterI.Conditional gene targeting in macrophages and granulocytes using LysMcre mice.Transgenic Res. (1999) 8:265–77. 10.1023/A:1008942828960
31.
AlvaJAZoveinACMonvoisinAMurphyTSalazarAHarveyNLet alVE-Cadherin-Cre-recombinase transgenic mouse: a tool for lineage analysis and gene deletion in endothelial cells.Dev Dyn. (2006) 235:759–67. 10.1002/dvdy.20643
32.
HallMESmithGHallJEStecDE.Systolic dysfunction in cardiac-specific ligand-inducible MerCreMer transgenic mice.Am J Physiol Heart Circ Physiol. (2011) 301:H253–60. 10.1152/ajpheart.00786.2010
33.
EckleTKoeppenMEltzschigH.Use of a hanging weight system for coronary artery occlusion in mice.J Vis Exp. (2011) 50:2526–2532. 10.3791/2526
34.
EckleTGrenzAKohlerDRedelAFalkMRolauffsBet alSystematic evaluation of a novel model for cardiac ischemic preconditioning in mice.Am J Physiol Heart Circ Physiol. (2006) 291:H2533–40. 10.1152/ajpheart.00472.2006
35.
LeeJWKoeppenMSeoSWBowserJLYuanXLiJet alTranscription-independent induction of ERBB1 through hypoxia-inducible factor 2A provides cardioprotection during ischemia and reperfusion.Anesthesiology. (2020) 132:763–80. 10.1097/ALN.0000000000003037
36.
KoeppenMHarterPNBonneySBonneyMReithelSZachskornCet alAdorAdora2b signaling on bone marrow derived cells dampens myocardial ischemia-reperfusion injury.Anesthesiology. (2012) 116:1245–57. 10.1097/ALN.0b013e318255793c
37.
DaleyJMThomayAAConnollyMDReichnerJSAlbinaJE.Use of Ly6G-specific monoclonal antibody to deplete neutrophils in mice.J Leukoc Biol. (2008) 83:64–70. 10.1189/jlb.0407247
38.
EckleTHartmannKBonneySReithelSMittelbronnMWalkerLAet alAdorAdora2b-elicited Per2 stabilization promotes a HIF-dependent metabolic switch crucial for myocardial adaptation to ischemia.Nat Med. (2012) 18:774–82. 10.1038/nm.2728
39.
CaiZZhongHBosch-MarceMFox-TalbotKWangLWeiCet alComplete loss of ischaemic preconditioning-induced cardioprotection in mice with partial deficiency of HIF-1 alpha.Cardiovasc Res. (2008) 77:463–70.
40.
YuAYShimodaLAIyerNVHusoDLSunXMcWilliamsRet alImpaired physiological responses to chronic hypoxia in mice partially deficient for hypoxia-inducible factor 1{alpha}.J Clin Invest. (1999) 103:691–6. 10.1172/JCI5912
41.
Soro-ArnaizILiQOYTorres-CapelliMMelendez-RodriguezFVeigaSVeysKet alRole of mitochondrial complex IV in age-dependent obesity.Cell Rep. (2016) 16:2991–3002. 10.1016/j.celrep.2016.08.041
42.
BergNKLiJKimBMillsTPeiGZhaoZet alHypoxia-inducible factor-dependent induction of myeloid-derived netrin-1 attenuates natural killer cell infiltration during endotoxin-induced lung injury.FASEB J. (2021) 35:e21334. 10.1096/fj.202002407R
43.
SeoSWKoeppenMBonneySGobelMThayerMHarterPNet alDifferential Tissue-specific function of AdorAdora2b in cardioprotection.J Immunol. (2015) 195:1732–43. 10.4049/jimmunol.1402288
44.
OngCWMFoxKEttorreAElkingtonPTFriedlandJS.Hypoxia increases neutrophil-driven matrix destruction after exposure to Mycobacterium tuberculosis.Sci Rep. (2018) 8:11475. 10.1038/s41598-018-29659-1
45.
SerafiniTColamarinoSALeonardoEDWangHBeddingtonRSkarnesWCet alNetrin-1 is required for commissural axon guidance in the developing vertebrate nervous system.Cell. (1996) 87:1001–14. 10.1016/S0092-8674(00)81795-X
46.
KellerMMirakajVKoeppenMRosenbergerP.Neuronal guidance proteins in cardiovascular inflammation.Basic Res Cardiol. (2021) 116:6. 10.1007/s00395-021-00847-x
47.
RosenbergerPSchwabJMMirakajVMasekowskyEMagerAMorote-GarciaJCet alHypoxia-inducible factor-dependent induction of netrin-1 dampens inflammation caused by hypoxia.Nat Immunol. (2009) 10:195–202. 10.1038/ni.1683
48.
EckleTKewleyEMBrodskyKSTakEBonneySGobelMet alIdentification of hypoxia-inducible factor HIF-1A as transcriptional regulator of the ADORA2B adenosine receptor during acute lung injury.J Immunol. (2014) 192:1249–56. 10.4049/jimmunol.1100593
49.
CaiZLuoWZhanHSemenzaGL.Hypoxia-inducible factor 1 is required for remote ischemic preconditioning of the heart.Proc Natl Acad Sci U.S.A. (2013) 110:17462–7. 10.1073/pnas.1317158110
50.
SarkarKCaiZGuptaRParajuliNFox-TalbotKDarshanMSet alHypoxia-inducible factor 1 transcriptional activity in endothelial cells is required for acute phase cardioprotection induced by ischemic preconditioning.Proc Natl Acad Sci U.S.A. (2012) 109:10504–9. 10.1073/pnas.1208314109
51.
YellonDMHausenloyDJ.Myocardial reperfusion injury.N Engl J Med. (2007) 357:1121–35. 10.1056/NEJMra071667
52.
KoeppenMMcNameeENBrodskyKSAherneCMFaigleMDowneyGPet alDetrimental role of the airway mucin Muc5ac during ventilator-induced lung injury.Mucosal Immunol. (2013) 6:762–75. 10.1038/mi.2012.114
53.
CorsetVNguyen-Ba-CharvetKTForcetCMoyseEChedotalAMehlenP.Netrin-1-mediated axon outgrowth and cAMP production requires interaction with adenosine Adora2b receptor.Nature. (2000) 407:747–50. 10.1038/35037600
54.
KeithBJohnsonRSSimonMC.HIF1alpha and HIF2alpha: sibling rivalry in hypoxic tumour growth and progression.Nat Rev Cancer. (2012) 12:9–22. 10.1038/nrc3183
55.
TakedaNO’DeaELDoedensAKimJWWeidemannAStockmannCet alDifferential activation and antagonistic function of HIF-{alpha} isoforms in macrophages are essential for NO homeostasis.Genes Dev. (2010) 24:491–501. 10.1101/gad.1881410
56.
JuCWangMTakEKimBEmontzpohlCYangYet alHypoxia-inducible factor-1alpha-dependent induction of miR122 enhances hepatic ischemia tolerance.J Clin Invest. (2021) 131:e140300. 10.1172/JCI140300
57.
GaoRYWangMLiuQFengDWenYXiaYet alHypoxia-inducible factor-2alpha reprograms liver macrophages to protect against acute liver injury through the production of interleukin-6.Hepatology. (2020) 71:2105–17. 10.1002/hep.30954
58.
MurryCEJenningsRBReimerKA.Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium.Circulation. (1986) 74:1124–36. 10.1161/01.CIR.74.5.1124
59.
GumbertSDKorkFJacksonMLVangaNGhebremichaelSJWangCYet alPerioperative acute kidney injury.Anesthesiology. (2020) 132:180–204. 10.1097/ALN.0000000000002968
60.
LeeJWKoJJuCEltzschigHK.Hypoxia signaling in human diseases and therapeutic targets.Exp Mol Med. (2019) 51:1–13. 10.1038/s12276-019-0235-1
61.
SerafiniTKennedyTEGalkoMJMirzayanCJessellTMTessier-LavigneM.The netrins define a family of axon outgrowth-promoting proteins homologous to C. elegans UNC-6.Cell. (1994) 78:409–24. 10.1016/0092-8674(94)90420-0
62.
MirakajVRosenbergerP.Immunomodulatory functions of neuronal guidance proteins.Trends Immunol. (2017) 38:444–56. 10.1016/j.it.2017.03.007
63.
SchlegelMKohlerDKornerAGranjaTStraubAGieraMet alThe neuroimmune guidance cue netrin-1 controls resolution programs and promotes liver regeneration.Hepatology. (2016) 63:1689–705. 10.1002/hep.28347
64.
MirakajVDalliJGranjaTRosenbergerPSerhanCN.Vagus nerve controls resolution and pro-resolving mediators of inflammation.J Exp Med. (2014) 211:1037–48. 10.1084/jem.20132103
65.
LiQWangPYeKCaiH.Central role of SIAH inhibition in DCC-dependent cardioprotection provoked by netrin-1/NO.Proc Natl Acad Sci U.S.A. (2015) 112:899–904. 10.1073/pnas.1420695112
66.
ZhangJCaiH.Netrin-1 prevents ischemia/reperfusion-induced myocardial infarction via a DCC/ERK1/2/eNOS s1177/NO/DCC feed-forward mechanism.J Mol Cell Cardiol. (2010) 48:1060–70. 10.1016/j.yjmcc.2009.11.020
67.
AherneCMCollinsCBMastersonJCTizzanoMBoyleTAWestrichJAet alNeuronal guidance molecule netrin-1 attenuates inflammatory cell trafficking during acute experimental colitis.Gut. (2012) 61:695–705. 10.1136/gutjnl-2011-300012
68.
OhtaASitkovskyM.Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage.Nature. (2001) 414:916–20. 10.1038/414916a
69.
KoeppenMEckleTEltzschigHK.Selective deletion of the A1 adenosine receptor abolishes heart-rate slowing effects of intravascular adenosine in vivo.PLoS One. (2009) 4:e6784. 10.1371/journal.pone.0006784
70.
LiXBergNKMillsTZhangKEltzschigHKYuanX.Adenosine at the interphase of hypoxia and inflammation in lung injury.Front Immunol. (2020) 11:604944. 10.3389/fimmu.2020.604944
71.
BowserJLPhanLHEltzschigHK.The hypoxia-adenosine link during intestinal inflammation.J Immunol. (2018) 200:897–907. 10.4049/jimmunol.1701414
72.
YuanXLeeJWBowserJLNeudeckerVSridharSEltzschigHK.Targeting hypoxia signaling for perioperative organ injury.Anesth Analg. (2018) 126:308–21. 10.1213/ANE.0000000000002288
73.
VafadarnejadERizzoGKrampertLArampatziPArias-LozaAPNazzalYet alDynamics of cardiac neutrophil diversity in murine myocardial infarction.Circ Res. (2020) 127:e232–49. 10.1161/CIRCRESAHA.120.317200
Summary
Keywords
hypoxia, myocardial infarction, polymorphonuclear neutrophil (PMN), reperfusion, heart, hypoxia inducible factor (HIF)
Citation
Heck-Swain KL, Li J, Ruan W, Yuan X, Wang Y, Koeppen M and Eltzschig HK (2022) Myeloid hypoxia-inducible factor HIF1A provides cardio-protection during ischemia and reperfusion via induction of netrin-1. Front. Cardiovasc. Med. 9:970415. doi: 10.3389/fcvm.2022.970415
Received
15 June 2022
Accepted
22 August 2022
Published
28 September 2022
Volume
9 - 2022
Edited by
Istvan Szokodi, University of Pécs, Hungary
Reviewed by
Claudia Penna, University of Turin, Italy; Timothy P. Fitzgibbons, University of Massachusetts Medical School, United States
Updates
Copyright
© 2022 Heck-Swain, Li, Ruan, Yuan, Wang, Koeppen and Eltzschig.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Michael Koeppen, michael.koeppen@med.uni-tuebingen.de
†These authors have contributed equally to this work
This article was submitted to Coronary Artery Disease, a section of the journal Frontiers in Cardiovascular Medicine
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.